Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus DECADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus DECADERM.
ALA-SCALP vs DECADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
Topical application of a 5% solution to the scalp twice daily.
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid